Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Gamco Investors INC. ET AL

Gamco Investors INC. ET AL lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 54.2% in the fourth quarter, Holdings Channel reports. The firm owned 563 shares of the biopharmaceutical company’s stock after acquiring an additional 198 shares during the period. Gamco Investors INC. ET AL’s holdings in Regeneron Pharmaceuticals were worth $401,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in REGN. Rakuten Securities Inc. grew its position in shares of Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 15 shares during the last quarter. OFI Invest Asset Management acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth $28,000. Avalon Trust Co purchased a new position in Regeneron Pharmaceuticals during the 4th quarter worth $36,000. Crowley Wealth Management Inc. acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at $36,000. Finally, Private Wealth Management Group LLC raised its holdings in shares of Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 39 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 2.5 %

Shares of Regeneron Pharmaceuticals stock opened at $563.16 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $525.99 and a fifty-two week high of $1,211.20. The business’s fifty day moving average is $645.94 and its two-hundred day moving average is $738.44. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The firm has a market cap of $61.57 billion, a PE ratio of 14.71, a P/E/G ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the previous year, the business earned $11.86 EPS. The firm’s revenue was up 10.3% on a year-over-year basis. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.63%. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Analysts Set New Price Targets

REGN has been the topic of several recent research reports. Sanford C. Bernstein dropped their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Truist Financial dropped their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. JPMorgan Chase & Co. decreased their price target on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating for the company in a report on Monday, March 31st. UBS Group cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Finally, BMO Capital Markets lowered their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, six have given a hold rating, eighteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $963.56.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.